Brucellosis Vaccines Market Size to Rise USD 389.50 Mn by 2033

The global brucellosis vaccines market size reached USD 242.70 million in 2023 and is projected to surpass around USD 389.50 million by 2033 growing at a CAGR of 4.84% from 2024 to 2033.

The global Brucellosis Vaccines Market is a rapidly evolving market that focuses on vaccines developed to combat the bacterial infection caused by Brucella species. Brucellosis, also known as Malta fever or Mediterranean fever, primarily affects livestock such as cattle, pigs, and sheep but can also infect humans through direct contact with infected animals or consumption of contaminated animal products. The infection can lead to severe economic losses in the livestock industry and presents a zoonotic risk to human health.

The market for brucellosis vaccines is driven by the need to control and prevent the spread of the disease in livestock, thereby reducing economic losses in the agricultural sector. As the demand for meat and dairy products continues to grow worldwide, the need for effective vaccination programs in livestock is expected to increase. Additionally, the potential risk of human infection through contact with infected animals or consumption of contaminated products further drives the demand for brucellosis vaccines.

Get a Sample: https://www.precedenceresearch.com/sample/4113

U.S. Brucellosis Vaccines Market Size in 2024 to 2033

The U.S. brucellosis vaccines market size was estimated at ?USD 83.49 million in 2023 and is expected to attain around USD 133.99 million by 2033 at a CAGR of 5.10% from 2024 to 2033.

In 2023, North America dominated the brucellosis vaccines market due to its higher incidence of the disease and advanced veterinary healthcare infrastructure. This has led to a significant demand for preventive measures and market growth. The region's research and development facilities and advanced diagnostic capabilities have also facilitated the production and adoption of advanced vaccines, further contributing to its leading position in the brucellosis vaccines market.

The Asia Pacific is expected to experience the highest growth rate in the forecast period due to the high demand for brucellosis vaccines, fueled by a large consumer base and increasing vaccine awareness.

Market Trends

Increasing Incidence of Brucellosis: The rising cases of brucellosis in both humans and animals have led to a growing demand for effective vaccines. This disease, caused by Brucella bacteria, can spread from animals to humans and is a concern in many parts of the world.

Technological Advancements: There have been significant advancements in vaccine development, including live attenuated vaccines and DNA vaccines. These new technologies have improved vaccine efficacy and safety, driving growth in the market.

Government Initiatives: Various governments are implementing vaccination programs to control brucellosis in livestock, which in turn helps to reduce the transmission of the disease to humans. These programs often involve subsidizing the cost of vaccines for farmers.

Global Trade Regulations: Regulations and international trade agreements concerning the health of livestock can affect the demand for brucellosis vaccines. Exporting countries need to comply with standards that require controlling diseases like brucellosis.

Type Insights

Brucellosis vaccines can be categorized into different types based on the form and nature of the vaccine. The most common types include live attenuated vaccines and subunit vaccines. Live attenuated vaccines, such as RB51 and Rev-1, contain weakened forms of the bacteria and are widely used for their efficacy in preventing the disease in livestock. Subunit vaccines contain purified components of the bacteria, offering a safer option for animals and humans.

Vaccine Insights

?The market can be segmented further by the specific vaccine used. Different vaccines are designed to target different species and strains of Brucella. For example, the RB51 vaccine is primarily used in cattle, while the Rev-1 vaccine is more suitable for sheep and goats. Research and development efforts focus on improving existing vaccines and developing new options for various animal species.

Application Insights

?Brucellosis vaccines are applied in various scenarios to control the disease's spread in both animals and humans. Key applications include livestock protection, where vaccines are used to prevent brucellosis in cattle, sheep, and goats. Another application is in wildlife management, as the disease can also affect wild animals. Vaccines are also utilized in efforts to protect human populations that may be at risk due to close contact with infected animals.

Distribution Channel Insights

The distribution of brucellosis vaccines occurs through various channels, including veterinary hospitals and clinics, agricultural supply stores, and online retail platforms. Veterinary hospitals and clinics play a key role in administering vaccines to livestock and educating farmers about disease prevention. Agricultural supply stores provide a convenient way for farmers to access vaccines, while online platforms offer a broader reach, especially in remote areas.

?Brucellosis Vaccines Market Recent Developments

• In March 2024, Boehringer Ingelheim, a renowned player in the animal health sector, collaborated with Square Pharmaceuticals to launch Aftovaxpur in Bangladesh. This advanced foot-and-mouth disease (FMD) vaccine is specifically formulated for ruminants, including cattle and sheep, aiming to enhance livestock health in the region.
• In October 2023, Zoetis, a leading animal health company based in the US, made headlines by acquiring Semex, a Canadian company specializing in bovine genetics and reproductive technology. This strategic move aims to bolster Zoetis’ standing in the cattle health market, particularly by enhancing its brucellosis vaccine offerings. The acquisition brings valuable expertise and a robust distribution network from Semex, strengthening Zoetis’ position in cattle breeding management.
• In April 2023, Cornell University College of Veterinary Medicine (CVM) scientists researched and developed a novel diagnostic test to identify Brucella canis. This test helps in the early diagnosis of this zoonotic disease, which can spread to humans through contact with infected dogs. This will boost vaccination over time.
• In July 2023, A notable development came from Hester Biosciences, an animal health company in India, with the launch of a new oral brucellosis vaccine for cattle. This innovative vaccine, based on the Brucella Abortus B19 strain, offers a more convenient and potentially cost-effective alternative to traditional injection-based vaccines. The introduction of this oral vaccine could open up new market segments, particularly in regions with limited resources, such as India.

Brucellosis Vaccines Market Companies

• Merck & Co.
• CZ Vaccines
• Colorado Serum Company
• Indian Immunologicals
• Hester Biosciences
• Veterinary Technologies Corporation
• Laboratorios Tornel
• Five Animal Health
• VETAL Animal Health Products Inc.

Immediate Delivery Available | Buy This Premium Research Report@ https://www.precedenceresearch.com/checkout/4113

Web: https://www.precedenceresearch.com/